Newsbenzinga
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
· Published
Article summary
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.
An excerpt from the original article.
Comments —
Loading comments…